Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas

Journal of the National Cancer Institute

Volumn 104, Issue 19, 2012, Pages 1458-1469

  Chou, Arthur P ^a   Chowdhury, Reshmi ^b   Li, Sichen ^b   Chen, Weidong ^b   Kim, Andrew J ^a   Piccioni, David E ^a   Selfridge, Julia M ^b   Mody, Reema R ^b   Chang, Stephen ^b   Lalezari, Shadi ^b   Lin, Jeffrey ^a   Sanchez, Desiree E ^b   Wilson, Ryan W ^b   Garrett, Matthew C ^a   Harry, Bret ^b   Mottahedeh, Jack ^b   Nghiemphu, Phioanh L ^b   Kornblum, Harley I ^b   Mischel, Paul S ^b   Prins, Robert M ^a   Yong, William H ^b   Cloughesy, Timothy ^b   Nelson, Stanley F ^b   Liau, Linda M ^a   Lai, Albert ^b   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISULFITE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; RETINOL BINDING PROTEIN; RETINOL BINDING PROTEIN 1; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CARCINOGENESIS; CONTROLLED STUDY; CPG ISLAND; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTANT; NEUROSURGERY; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; PROPORTIONAL HAZARDS MODEL; PROTEIN ANALYSIS; RESTRICTION SITE; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SURVIVAL RATE; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; WILD TYPE;

ADULT; AGED; BLOTTING, WESTERN; BRAIN NEOPLASMS; CPG ISLANDS; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; RESTRICTION MAPPING; RETINOL-BINDING PROTEINS, CELLULAR; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFITES; TRETINOIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84867320257     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs357     Document Type: Article

References (58)

1. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807-1812.
2. Gross S, Cairns RA, Minden MD, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010;207(2):339-344.
3. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17(3):225-234.
4. Lai A, Kharbanda S, Pope WB, et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol. 2011;29(34):4482-4490.
5. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174(4):1149-1153.
6. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773.
7. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739-744.
8. Noushmehr H, Weisenberger DJ, Diefes K, et al.; Cancer Genome Atlas Research Network. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17(5):510-522.
9. Christensen BC, Smith AA, Zheng S, et al. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst. 2011;103(2):143-153.
10. Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012;483(7390):479-483.
11. Laffaire J, Everhard S, Idbaih A, et al. Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. Neuro-oncology. 2011;13(1):84-98.
12. Gargiulo G, Minucci S. Epigenomic profiling of cancer cells. Int J Biochem Cell Biol. 2009;41(1):127-135.
13. Zilberman D, Henikoff S. Genome-wide analysis of DNA methylation patterns. Development. 2007;134(22):3959-3965. (Pubitemid 350269413)
14. Meissner A, Gnirke A, Bell GW, Ramsahoye B, Lander ES, Jaenisch R. Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis. Nucleic Acids Res. 2005;33(18):5868-5877. (Pubitemid 41742606)
15. Meissner A, Mikkelsen TS, Gu H, et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature. 2008;454(7205):766-770.
16. Boerman MH, Napoli JL. Cellular retinol-binding protein-supported retinoic acid synthesis. Relative roles of microsomes and cytosol. J Biol Chem. 1996;271(10):5610-5616.
17. Blomhoff R, Blomhoff HK. Overview of retinoid metabolism and function. J Neurobiol. 2006;66(7):606-630. (Pubitemid 43941649)
18. Ghyselinck NB, B?ik C, Sapin V, et al. Cellular retinol-binding protein I is essential for vitamin A homeostasis. EMBO J. 1999;18(18):4903-4914. (Pubitemid 29443793)
19. Tang XH, Gudas LJ. Retinoids, retinoic acid receptors, and cancer. Annu Rev Pathol. 2011;6:345-364.
20. Network TCGAR. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061-1068.
21. Stupp R, Mason WP, van den Bent MJ, et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996. (Pubitemid 40349501)
22. Wanner IB. An in vitro trauma model to study rodent and human astrocyte reactivity. Methods Mol Biol. 2012;814:189-219.
23. Li H, Handsaker B, Wysoker A, et al.; 1000 Genome Project Data Processing Subgroup. The sequence alignment/map format and SAM tools. Bioinformatics. 2009;25(16):2078-2079.
24. Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J Mol Biol. 1987;196(2):261-282. (Pubitemid 17122132)
25. Tran A, Escovedo C, Migdall-Wilson J, et al. In silico enhanced restriction enzyme based methylation analysis of the human glioblastoma genome using agilent 244K CpG island microarrays. Front Neurosci. 2009;3:57.
26. Storey JD. A direct approach to false discovery rates. J R Stat Soc Ser B Stat Methodol. 2002;64(3):479-498.
27. Rozen S, Skaletsky HJ. Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S MS, ed. Bioinformatics Methods and Protocols: Methods in Molecular Biology. Totowa, NJ: Humana Press; 2000:365-386.
28. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.
29. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA. 2001;98(1):31-36. (Pubitemid 32095858)
30. Kawaguchi R, Yu J, Ter-Stepanian M, et al. Receptor-mediated cellular uptake mechanism that couples to intracellular storage. ACS Chem Biol. 2011;6(10):1041-1051.
31. Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol. 2009;27(34):5743-5750.
32. Dunn J, Baborie A, Alam F, et al. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer. 2009;101(1):124-131.
33. Karayan-Tapon L, Quillien V, Guilhot J, et al. Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J Neurooncol. 2010;97(3):311-322.
34. Cao VT, Jung TY, Jung S, et al. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas. Neurosurgery. 2009;65(5):866-875; discussion 875.
35. Sonoda Y, Yokosawa M, Saito R, et al. O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma. Int J Clin Oncol. 2010;15(4):352-358.
36. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003. (Pubitemid 40349502)
37. Malley DS, Hamoudi RA, Kocialkowski S, Pearson DM, Collins VP, Ichimura K. A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts. Acta Neuropathol. 2011;121(5):651-661.
38. Oster B, Thorsen K, Lamy P, et al. Identification and validation of highly frequent CpG island hypermethylation in colorectal adenomas and carcinomas. Int J Cancer. 2011;129(12):2855-2866.
39. Ernst A, Campos B, Meier J, et al. De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures. Oncogene. 2010;29(23):3411-3422.
40. Banerjee S, Bacanamwo M. DNA methyltransferase inhibition induces mouse embryonic stem cell differentiation into endothelial cells. Exp Cell Res. 2010;316(2):172-180.
41. Gömöri E Pál J, Mészáros I, Dóczi T, Matolcsy A. Epigenetic inactivation of the hMLH1 gene in progression of gliomas. Diagn Mol Pathol. 2007;16(2):104-107. (Pubitemid 47164743)
42. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118(4):469-474.
43. Mellai M, Piazzi A, Caldera V, et al. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors. J Neurooncol. 2011;105(2):345-357.
44. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553-567.
45. Pike BL, Greiner TC, Wang X, et al. DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status. Leukemia. 2008;22(5):1035-1043. (Pubitemid 351689886)
46. Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of a-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19(1):17-30.
47. Zetterstr RH, Simon A, Giacobini MM, Eriksson U, Olson L. Localization of cellular retinoid-binding proteins suggests specific roles for retinoids in the adult central nervous system. Neuroscience. 1994;62(3):899-918.
48. Tafti M, Ghyselinck NB. Functional implication of the vitamin A signaling pathway in the brain. Arch Neurol. 2007;64(12):1706-1711. (Pubitemid 350254931)
49. Maden M. Retinoic acid in the development, regeneration and maintenance of the nervous system. Nat Rev Neurosci. 2007;8(10):755-765. (Pubitemid 47462115)
50. Bistulfi G, Pozzi S, Ren M, Rossetti S, Sacchi N. A repressive epigenetic domino effect confers susceptibility to breast epithelial cell transformation: implications for predicting breast cancer risk. Cancer Res. 2006;66(21):10308- 10314. (Pubitemid 44799749)
51. Toki K, Enokida H, Kawakami K, et al. CpG hypermethylation of cellular retinol-binding protein 1 contributes to cell proliferation and migration in bladder cancer. Int J Oncol. 2010;37(6):1379-1388.
52. Jerimo C, Henrique R, Oliveira J, et al. Aberrant cellular retinol binding protein 1 (CRBP1) gene expression and promoter methylation in prostate cancer. J Clin Pathol. 2004;57(8):872-876. (Pubitemid 39061439)
53. Orlandi A, Ferlosio A, Ciucci A, et al. Cellular retinol binding protein-1 expression in endometrial hyperplasia and carcinoma: diagnostic and possible therapeutic implications. Mod Pathol. 2006;19(6):797-803. (Pubitemid 43780449)
54. Campos B, Centner FS, Bermejo JL, et al. Aberrant expression of retinoic acid signaling molecules influences patient survival in astrocytic gliomas. Am J Pathol. 2011;178(5):1953-1964.
55. Barbus S, Tews B, Karra D, et al. Differential retinoic acid signaling in tumors of long-and short-term glioblastoma survivors. J Natl Cancer Inst. 2011;103(7):598-606.
56. Yung WK, Kyritsis AP, Gleason MJ, Levin VA. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. Clin Cancer Res. 1996;2(12):1931-1935. (Pubitemid 27006624)
57. Jaeckle KA, Hess KR, Yung WK, et al.; North American Brain Tumor Consortium. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2003;21(12):2305-2311. (Pubitemid 46621868)
58. See SJ, Levin VA, Yung WK, Hess KR, Groves MD. 13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme. Neuro-oncology. 2004;6(3):253-258. (Pubitemid 39136508)